KLSE (MYR): YONGTAI (7066)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
0.26
Today's Change
+0.01 (4.00%)
Day's Change
0.245 - 0.27
Trading Volume
5,259,500
2024-08-07
2024-08-06
2024-08-01
2024-08-01
2024-08-01
2024-08-01
2024-08-01
2024-08-01
2024-07-31
2024-07-31
2024-07-30
2024-07-30
2024-07-30
2024-07-30
gateway31
333 posts
Posted by gateway31 > 2020-12-25 23:03 | Report Abuse
Google Translate:
Financial Associated Press (Shenzhen, reporter Ding Rong), Malaysian listed company YONGTAIBERHAD recently announced that the company has reached cooperation with Shenzhen Kangtai Biological Products Co., Ltd. and KLINSELSDNBHD to promote Kangtai Bio-New Crown inactivated vaccine in Malaysia to carry out phase III clinical trials . After the phase III clinical trial is successfully concluded or emergency use rights are obtained in Malaysia, the company will have the exclusive commercialization rights. The two parties plan to cooperate with about 100 million doses, a five-year vaccine procurement plan.
A person close to Kangtai Biologicals (300601.SZ) said: "At present, Kangtai Biologicals Covid-19 vaccine research and development continues to advance. This time, it is cooperating with Malaysia YONGTAIBERHAD to jointly promote the international multi-center phase III clinical trial of the new coronavirus inactivated vaccine."
Regarding the new coronavirus inactivated vaccine (Vero cell), Kangtai Biotechnology received a drug clinical trial approval document issued by the National Medical Products Administration in September this year. After review and review by a special expert group, the product was approved for clinical trials in an emergency. The indication is Prevent new coronavirus pneumonia caused by new coronavirus infection. Information from the China Clinical Trial Registration Center shows that the vaccine has entered the phase II clinical trial in October.
It is worth mentioning that in addition to the independently developed inactivated vaccine for the new crown, Kangtai Biotech also cooperates with AstraZeneca in the ChAdOx1 adenovirus vector vaccine. The viral vector COVID-19 vaccine developed by the company and AstraZeneca is currently in the phase III clinical trial. It is a rapidly progressing COVID-19 vaccine project in the world. It is expected to be used urgently in Europe and the United States by the end of the year. It is expected to be introduced to China in the future. The time for domestic clinical trials is expected. It will also be shortened. In addition, Kangtai Biological also deployed recombinant VSV virus vector vaccine.
The Financial Association stated: The content of the article is for reference only and does not constitute investment advice. Investors operate accordingly at their own risk.